| Literature DB >> 34634114 |
Kelly Copeland Cara, Andrew R Beauchesne, Taylor C Wallace, Mei Chung.
Abstract
One hundred percent orange juice (OJ) has no added sugar, naturally contains flavonoids and ascorbic acid, and can modulate the body's oxidative and inflammatory systems. This scoping review, systematic review, and meta-analysis investigated associations between 100% OJ and markers of inflammation or oxidation in healthy adults and those at risk for chronic diseases. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and scoping review extension. Literature in English was searched to July 2021 in Embase and 4 Ovid platform databases. Clinical and observational studies of any duration were eligible. Cochrane Collaboration tools were used to assess the risk of bias in controlled trials. Strength of evidence was determined using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The scoping review presents a qualitative synthesis of evidence in summary and results tables. Twenty-one interventional studies (16 controlled trials and 5 before-after studies) conducted in 307 healthy and 327 at-risk participants were included. Six common markers [C-reactive protein (CRP) or high-sensitivity CRP (hs-CRP), IL-6, TNF-α, malondialdehyde (MDA), oxidized LDL (oxLDL), and antioxidant capacity] measured across 16 studies were systematically reviewed, and results were synthesized narratively. Random-effects model meta-analyses were conducted on 10 studies reporting hs-CRP, IL-6, and/or MDA. After consuming 100% OJ, healthy and at-risk participants showed significantly lower IL-6 concentrations (pooled net difference: -1.51 pg/mL; 95% CI: -2.31, -0.70) and lower, but nonsignificant, hs-CRP (pooled net change: -0.58 mg/L; 95% CI: -1.22, 0.05) and MDA (crossover trials pooled net difference: -0.06 μmol/L; 95% CI: -0.19, 0.08). Findings suggest that 100% OJ may reduce inflammation, but results should be interpreted with caution due to moderate risk of bias, very low strength of evidence, and the low number of subjects. This study was registered on PROSPERO (https://www.crd.york.ac.uk/prospero/) as CRD42021235438.Entities:
Keywords: 100% juice; C-reactive protein; citrus; cytokines; fruit and vegetable juices; inflammation; orange juice; oxidative stress
Mesh:
Substances:
Year: 2022 PMID: 34634114 PMCID: PMC8803484 DOI: 10.1093/advances/nmab101
Source DB: PubMed Journal: Adv Nutr ISSN: 2161-8313 Impact factor: 8.701
FIGURE 1PRISMA flowchart of literature search and study selection. 1Twenty-two articles reporting on 21 studies. hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Summary of study characteristics overall and by markers of inflammation or oxidative stress most reported by the 21 included studies[1]
| Top-reported markers of inflammation and oxidative stress | |||||||
|---|---|---|---|---|---|---|---|
| Characteristics | Total | CRP or hs-CRP | IL-6 | TNF-α | MDA | OxLDL | Antioxidant capacity |
|
| 21 | 9 | 5 | 5 | 6 | 3 | 7 |
| Design, | |||||||
| Randomized, crossover | 11 (52%) | 4 (44%) | 4 (80%) | 2 (40%) | 3 (50%) | 2 (67%) | 3 (43%) |
| Randomized, parallel | 1 (5%) | 1 (11%) | 0 (0%) | 0 (0%) | 1 (17%) | 0 (0%) | 1 (14%) |
| Nonrandomized, parallel | 4 (19%) | 1 (11%) | 1 (20%) | 1 (20%) | 1 (17%) | 1 (33%) | 0 (0%) |
| Before-after | 5 (24%) | 3 (33%) | 0 (0%) | 2 (40%) | 1 (17%) | 0 (0%) | 3 (43%) |
| Region, | |||||||
| North America | 4 (19%) | 0 (0%) | 1 (20%) | 1 (20%) | 0 (0%) | 0 (0%) | 1 (14%) |
| South America | 4 (19%) | 3 (33%) | 1 (20%) | 1 (20%) | 2 (33%) | 0 (0%) | 3 (43%) |
| Europe | 11 (52%) | 5 (56%) | 2 (40%) | 3 (60%) | 3 (50%) | 3 (100%) | 2 (29%) |
| Middle East | 1 (5%) | 1 (11%) | 1 (20%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Africa | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (17%) | 0 (0%) | 1 (14%) |
| Sample size, | |||||||
| <10 | 2 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| 10–20 | 8 (38%) | 2 (22%) | 1 (20%) | 1 (20%) | 3 (50%) | 1 (33%) | 4 (57%) |
| 21–30 | 4 (19%) | 2 (22%) | 2 (40%) | 1 (20%) | 0 (0%) | 0 (0%) | 0 (0%) |
| 31–50 | 5 (24%) | 4 (44%) | 2 (40%) | 3 (60%) | 1 (17%) | 1 (33%) | 2 (29%) |
| 51–100 | 2 (10%) | 1 (11%) | 0 (0%) | 0 (0%) | 2 (33%) | 1 (33%) | 1 (14%) |
| Total study duration, | |||||||
| Acute (≤1 wk) | 2 (10%) | 0 (0%) | 1 (20%) | 1 (20%) | 0 (0%) | 0 (0%) | 0 (0%) |
| >1 to 4 wk | 8 (38%) | 1 (11%) | 2 (40%) | 1 (20%) | 2 (33%) | 0 (0%) | 2 (29%) |
| >1 to 3 mo | 10 (48%) | 8 (89%) | 2 (40%) | 3 (60%) | 3 (50%) | 2 (67%) | 5 (71%) |
| >3 to 8 mo | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (17%) | 1 (33%) | 0 (0%) |
| Intervention/arm duration, | |||||||
| Acute (≤24 h) | 9 (43%) | 1 (11%) | 3 (60%) | 2 (40%) | 1 (17%) | 1 (33%) | 2 (29%) |
| >1 to 7 d | 1 (5%) | 1 (11%) | 1 (20%) | 1 (20%) | 0 (0%) | 0 (0%) | 0 (0%) |
| >1 to 4 wk | 6 (29%) | 3 (33%) | 1 (20%) | 0 (0%) | 2 (33%) | 1 (33%) | 1 (14%) |
| >1 to 3 mo | 5 (24%) | 4 (44%) | 0 (0%) | 2 (40%) | 3 (50%) | 1 (33%) | 4 (57%) |
| Mean or median age, | |||||||
| 18–25 y | 4 (19%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (33%) | 0 (0%) | 3 (43%) |
| >25 to 50 y | 15 (71%) | 8 (89%) | 5 (100%) | 5 (100%) | 3 (50%) | 3 (100%) | 4 (57%) |
| >50 y | 2 (10%) | 1 (11%) | 0 (0%) | 0 (0%) | 1 (17%) | 0 (0%) | 0 (0%) |
| Health status, weight status,[ | |||||||
| Healthy, normal weight | 10 (48%) | 2 (22%) | 3 (60%) | 1 (20%) | 2 (33%) | 1 (33%) | 3 (43%) |
| Generally healthy, overweight | 4 (19%) | 2 (22%) | 0 (0%) | 1 (20%) | 2 (33%) | 0 (0%) | 2 (29%) |
| At-risk, overweight | 3 (14%) | 2 (22%) | 1 (20%) | 1 (20%) | 0 (0%) | 1 (33%) | 0 (0%) |
| At-risk, obese | 4 (19%) | 3 (33%) | 1 (20%) | 2 (40%) | 2 (33%) | 1 (33%) | 2 (29%) |
| Comparator intervention,[ | |||||||
| Water | 4 (19%) | 0 (0%) | 2 (40%) | 1 (20%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Glucose or sugar beverage | 5 (24%) | 1 (11%) | 3 (60%) | 2 (40%) | 0 (0%) | 1 (33%) | 0 (0%) |
| Non-100% OJ | 4 (19%) | 2 (22%) | 2 (40%) | 1 (20%) | 1 (17%) | 2 (67%) | 0 (0%) |
| Placebo juice | 5 (24%) | 1 (11%) | 1 (20%) | 1 (20%) | 1 (17%) | 0 (0%) | 4 (57%) |
| Other beverage | 2 (10%) | 0 (0%) | 1 (20%) | 1 (20%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Without OJ | 4 (19%) | 2 (22%) | 0 (0%) | 0 (0%) | 3 (50%) | 1 (33%) | 2 (29%) |
| No comparator | 5 (24%) | 4 (44%) | 0 (0%) | 2 (40%) | 1 (17%) | 0 (0%) | 3 (43%) |
Values of 0 (0%) indicate potential gaps in the literature, where no study in the review met the given characteristic. CRP, C-reactive protein; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde (a secondary lipid peroxidation marker); OJ, orange juice; OxLDL, oxidized LDL.
Categories for weight status based on BMI (in kg/m2): normal-weight BMI = 18.5–24.9, overweight BMI = 25.0–29.9, obese BMI = ≥30.0 (25).
The sum of each column is greater than the column total n due to multiple comparators for some studies.
Study and participant characteristics with results for markers of inflammation or oxidative stress and key findings from included articles[1]
| Author, year (ref); country | Study design; overall risk-of-bias judgment | Funding source | Total | Mean (SD)[ | Health status; smoking status | Mean (SD)[ | Study duration | 100% OJ group(s); orange variety or type | Comparison group(s) | Results for 100% OJ group(s)[ | Key findings for 100% OJ vs. comparison group(s)[ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asgary et al., 2014 ( | Crossover RCT; some concern | Nonprofit | 22; 31.8 | ∼34.5 (11, 12) | 100% healthy; nonsmokers | ∼24.5 (4.3, 5.5); normal or healthy | 10 wk total: 4 wk per intervention and 2-wk washout | 1000 mL/d freshly squeezed OJ; | 1000 mL/d commercial OJ from concentrate | Serum VCAM-1: - -Serum E-selectin: - -Serum hs-CRP: - -Serum IL-6: 0 | There were marginally significant differences in serum hs-CRP concentrations after intake of OJ from concentrate (lower hs-CRP at endpoint) and 100% OJ (greater decrease from baseline hs-CRP) |
| Azzini et al., 2017 ( | Before-after; NA | Government | 20; 0 | 36 (7) | At-risk; nonsmokers | 34.4 (4.8); obese | 12 wk | 500 mL/d commercial pasteurized red OJ; NR | NA | Plasma TAC [FRAP assay]: 0Plasma CRP: 0Plasma TNF-α: 0Plasma leptin: 0 | No comparator |
| Boussetta et al., 2020 ( | Crossover RCT; high | None | 11; NR | 22.5 (0.5) | 100% healthy (soccer players); nonsmokers | 23.2 (0.4); normal or healthy | ∼2 wk total: 2.5 h per intervention, ≥72-h washout, 1 wk between trials (polluted and nonpolluted) | 500 mL fresh blood OJ with no chemical products added; NR | 500 mL placebo juice | [After an intense bout of exercise]Plasma TAC [TAS assay]: ++ (polluted and nonpolluted area)Plasma MDA: ++ (polluted and nonpolluted area) | Compared to placebo juice, consuming 100% OJ before an intense bout of exercise resulted in significantly lower plasma MDA after exercise in both polluted and nonpolluted areas |
| Buscemi et al., 2012 ( | Crossover RCT; high | None | 21; 52.6 | 48 (13) | At-risk (nondiabetic subjects at increased cardiovascular risk with >2 diagnostic criteria of MetS); some smokers | 32.1 (4.9); obese | ∼2.5 wk total: 1 wk per intervention, 3-d washout | 500 mL/d commercial pasteurized OJ; | 500 mL/d placebo juice with water, orange aroma, colorants (azorubin and tartrazine), sucrose, and citric acid | Serum IL-6: - -Serum TNF-α: - -Serum hs-CRP: - -Plasma protein carbonyl groups: 0 | Compared to placebo juice, consuming 100% OJ significantly reduced inflammation as indicated by lower serum concentrations of IL-6, TNF-α, and hs-CRP |
| Cerletti et al., 2015 ( | Crossover RCT; some concern | Government | 18; 50 | 36.9 (10.5) | At-risk (≥1 cardiovascular risk factor including 58% with prediabetes); some smokers | 26.8 (4.0); overweight | ∼1 wk total: 2 h per intervention, 7 ± 2-d washout |
| 1 L water | [After consuming a fatty meal]WBC count: 0 (both juices)PMN MPO release: - (blond OJ), - - (red OJ) | Compared to water, consuming blond OJ or red OJ with a fatty meal significantly attenuated rise in WBC counts and moderately attenuated MPO release ( |
| Chaves et al., 2017 ( | Crossover RCT; some concern | Government | 12; 41.7 | NR (NR) | 100% healthy; smoking status NR | Range: 20–25; normal or healthy | ∼2 wk total: 5 h per intervention, ≥1-wk washout between interventions | 500 mL commercial pasteurized 100% OJ; NR |
| [After consuming a high-fat, high-carbohydrate meal]Serum IL-4: 0Serum IL-6: decreased ( | A high-fat, high-carbohydrate meal with water or the isocaloric beverage increased IL-6, but inflammation was significantly mitigated with 100% OJ which reduced IL-6. Induced PBMC proteins (for all 3 beverages): apolipoprotein A-II, ceruloplasmin, and hemopexin |
| Deopurkar et al., 2010 ( | Nonrandomized parallel controlled intervention; some concern | Government and nonprofit | 48; NR | NR (NR) | 100% healthy; smoking status NR | Range: 21.5–24.4; normal or healthy | 5 h | 300 kcal commercial not from concentrate Florida OJ; NR |
| TNF-α mRNA: 0IL-1β mRNA: 0IL-6 mRNA: 0NF-κB: 0TLR-2 mRNA or protein: 0TLR-4 mRNA or protein: 0SOCS1 mRNA: 0SOCS3 mRNA or protein: 0SOCS7 mRNA: 0Plasma endotoxin concentrations: 0 (LPS and LBP) | Compared[ |
| Dong et al., 2016 ( | Crossover RCT; some concern | Industry | 39; 100 | 48 (SEM: 1) | At-risk (≥1 cardiometabolic risk factor including mild hypercholesterolemia); nonsmokers | 28.4 (0.4); overweight | ∼6 wk total: 7 h per intervention, 2-wk washout between interventions |
|
| [After consuming a high-fat meal[ | No differences |
| Dourado et al., 2015 ( | Before-after; NA | Industry | 50; NR | ∼35.6 (8.6, 10.5) | Generally healthy; smoking status NR | ∼25.9 (1.7, 3.0); overweight | 8 wk | 750 mL/d 100% OJ without added sugars; NR | NA | [Same findings for participants with normal weight and overweight]Lipid peroxidation [TBARS assay] as MDA: - -Serum TAC [DPPH method]: ++Serum hs-CRP: - -Serum IL-4: 0Serum IL-10: 0Serum IL-12: ++Serum TNF-α: 0Serum IFN-γ: 0 | No comparator |
| Ghanim et al., 2010 ( | Nonrandomized parallel controlled intervention; some concern | Government and nonprofit | 30; NR | NR (NR) | 100% healthy; smoking status NR | Range: 20–25; normal or healthy | 5 h | 300 kcal commercial pasteurized not from concentrate OJ; NR |
| [After consuming a high-fat, high-carbohydrate meal]ROS-PMN: ++ROS-MNC: ++p47phox protein: 0TLR2 mRNA or protein: 0TLR4 mRNA or protein: 0SOCS-3 protein: 0SOCS-3 mRNA: only baseline reportedp38 protein: 0MMP-9 mRNA: 0Plasma MMP-9: 0Plasma endotoxins (LPS): 0Phosphorylated p38 protein to p38 ratio: only baseline reported | Compared[ |
| Guarnieri et al., 2007 ( | Crossover RCT; some concern | NR | 7; 0 | 26 (2.1) | 100% healthy; nonsmokers | 20.1 (1.4); normal or healthy | ∼4 wk total: 24 h per intervention, 2-wk washout between interventions | 300 mL commercial pasteurized blood OJ; NR |
| H2O2-induced MNBC DNA damage (strand breaks): - - | Compared[ |
| Hollands et al., 2018 ( | Crossover RCT; some concern | Government and nonprofit | 45; 48.8 | 52.2 (13.6) | At-risk (all with abdominal obesity based on waist circumference); nonsmokers | 29.0 (5.1); overweight | ∼11 wk total: 4 wk per intervention, ≥3-wk washout | 500 mL/d commercial not from concentrate: | None | Serum hs-CRP: 0[ | No difference |
| Johnston et al., 2005 ( | Before-after with multiple arms; NA | Nonprofit | 6; 0 | 36.8 (4.5) | 100% healthy; nonsmokers | 26.8 (3.3); overweight | >2 wk total: 2 h per intervention, 8 d between 100% or comparator OJs 1 and 2, but washout between 100% OJ and comparator trials NR | 237 mL commercial pasteurized not from concentrate 100% pure OJ without pulp: | 237 mL OJ reconstituted from frozen concentrate: | Plasma LPOs [TBARS assay]: 0 (freshly opened OJ and after 8 days of storage) | Day 1 preparation[ |
| Perrone et al., 2020 ( | Nonrandomized parallel controlled intervention; high | NR | 20; 100 | ∼27.3 (2.8, 3.2) | 100% healthy (professional athletes practicing cross-country skiing); nonsmokers | ∼23.4 (2.8, 3.2); normal or healthy | ∼4 wk | Common diet plus 500 mL/d 100% pure bergamot juice; | Common diet with no OJ | [After 30 d intensive training]hs-CRP: - -oxLDL: 0 | Compared to no OJ, 100% OJ attenuated increases in oxLDL after 30 d intensive training and significantly improved hs-CRP |
| Pittaluga et al., 2013 ( | Nonrandomized parallel controlled intervention; high | Nonprofit | 22; 0 | ∼68.7 (2.7, 5.1) | Generally healthy; nonsmokers | ∼26.0 (2.1, 3.2); overweight | 4-wk intervention; 24 h per trial with exhaustive exercise | 750 mL/d fresh juice from pigmented red oranges; | No OJ | [At rest and after a bout of exhaustive exercise[ | Compared[ |
| Rangel-Huerta et al., 2015 ( | Crossover RCT; some concern | Industry | 100; NR | NR (NR) | At-risk (most with alterations in ≥1 clinical sign of metabolic syndrome); nonsmokers | ∼33.2 (0.5, 0.6); obese | 31 wk total: 12 wk per intervention, 7-wk washout | 500 mL/d commercial OJ with normal amount of polyphenols; NR | 500 mL/d commercial OJ enriched with polyphenols extracted from orange albedo and pulp | Plasma GSH: 0Plasma GSSG: 0Urine 8-iso-PGF2α: - -Urine 8-OHdG: - -Plasma oxLDL: 0Plasma LPOs: - -Plasma MDA: 0 | Compared to enriched OJ, consuming 100% OJ resulted in significantly reduced plasma LPO levels and a greater reduction in urine 8-OHdG, but enriched OJ produced significantly lower urine 8-OHdG concentrations |
| Rangel-Huerta et al., 2017 ( | Subgroup analysis of crossover RCT (nonrandom selection of subjects from only sequence 1); NA | Industry | 30; NR | ∼44 (9, 11) | At-risk (most with alterations in ≥1 clinical sign of metabolic syndrome); nonsmokers | ∼32.2 (3.6, 4.2); obese | 12 wk | 500 mL/d commercial OJ with normal amount of polyphenols; NR | 500 mL/d commercial OJ enriched with polyphenols (hesperidin, narirutin, and didymin) obtained from albedo and pulp | 9-HODE + 13-HODE: 0Serum 5-HETE: ++Serum 12-HETE: 0Derivate dihydroxy fatty acids: 0 (12,13-DiHOME), 0 (9,10-DiHOME) | Consuming polyphenol-enriched OJ significantly decreased metabolites 9-HODE + 13-HODE, 12,13-DiHOME, and 9,10-DiHOME; significantly increased 12-HETE; and attenuated increases in 5-HETE seen with 100% OJ. |
| Ribeiro et al., 2017 ( | Parallel RCT; some concern | Industry | 84; 30.8 | 36 (1) | At-risk; smoking status NR | 33 (3); obese | 12 wk | Reduced-calorie diet plus 500 mL/d commercial 100% OJ; Pera Rio oranges | Reduced-calorie diet with no OJ | Serum hs-CRP: - -Serum lipid peroxidation [TBARS assay] as MDA: - -Serum TAC [radical 2,20-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) assay]: 0 | Compared to no OJ, consuming 100% OJ produced significantly lower serum hs-CRP concentrations at 12 wk |
| Riso et al., 2005 ( | Crossover RCT; high | Government | 16; 0 | NR (NR) | 100% healthy; smoking status NR | Range: 16.0–23.3; normal or healthy | 9–10 wk total: 3–4 wk per intervention (where 1 group had an extra week of juice), 3-wk washout | Standardized diet plus 600 mL/d commercial pasteurized blood OJ; NR | Standardized diet with no OJ | Plasma TAC [reduction by antioxidants, of Cu2+ to Cu+]: 0Plasma MDA: 0Urinary 11-Dehydro-TXB2: 0H2O2-induced DNA damage (% DNA in tail): 0 (21 d juice intake group), - - (28 d juice intake group) | Compared[ |
| Sánchez-Moreno et al., 2003 ( | Before-after; NA | Government | 12; 50 | 22 (3) | 100% healthy; some smokers | 22.2 (1.6); normal or healthy | 2 wk | 500 mL/d commercial OJ; NR | NA | Plasma 8- | No comparator |
| Silveira et al., 2015 ( | Before-after; NA | Government | 35;54.3 | ∼36 (9.0, 9.4, 10.3, 11.8) | Generally healthy; nonsmokers | ∼26.0 (2, 3); overweight | 8 wk | 500 mL/d frozen, ready-to-drink red OJ; | NA | Serum hs-CRP: - - (normal weight and overweight/obese)Serum antioxidant capacity [DPPH method]: ++ (normal weight and overweight/obese) | No comparator |
| Snyder et al., 2011 ( | Crossover RCT; some concern | Nonprofit | 16; NR | 20.1 (NR) | 100% healthy; nonsmokers | 23.8 (range: 20–27.4); normal or healthy | 4 wk total: 3 h per intervention, 1-wk washout between interventions | 591 mL fresh-squeezed OJ; navel oranges | 591 mL placebo juice: | Serum antioxidant capacity [ORAC assay]: - -Serum lipoprotein oxidation: - - (AUC as overall measurement of lipoprotein diene formation), ++ (lag time to onset of diene formation) | Compared[ |
CRP, C-reactive protein; Dehydro-TXB2, dehydrothromboxane B2; DPPH, 2,2-diphenyl-1-picrylhydrazyl; FRAP, ferric reducing antioxidant power; hs-CRP, high-sensitivity C-reactive protein; DiHOME, dihydroxyoctadecanoic acid; GSH, reduced glutathione; GSH/GSSG, glutathione redox ratio; GSSG, oxidized glutathione; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; iso-, isoprostane; LBP, lipopolysaccharide-binding protein; LPO, lipid peroxidation; MDA, malondialdehyde (a secondary lipid peroxidation marker); MMP, matrix metallopeptidase; MNBC, mononuclear blood cell; MNC, mononuclear cell; NA, not applicable; NR, not reported; OJ, orange juice; ORAC, oxygen radical absorbance capacity; oxLDL, oxidized LDL; PBMC, peripheral blood mononuclear cell; PGF, prostaglandin F; PMN, polymorphonuclear cell; PMN MPO, intracellular polymorphonuclear leukocyte myeloperoxidase; RCT, randomized controlled trial; ref, reference; ROS, reactive oxygen species; SOCS, suppresser of cytokine signaling; TAC, total antioxidant capacity; TAS, total antioxidant status; TBARS, thiobarbituric acid reactive substance; TLR, Toll-like receptor; VCAM, vascular endothelial adhesion molecule; WBC, white blood cell; 8-OHdG, 8-hydroxy-2′-deoxyguanosine.
If total mean (SD) was not reported for study participants, the table presents means as calculated weighted averages (indicated by the “∼” symbol) and separate group SDs reported in the original study (presented in parentheses separated by a comma).
Categories for weight status based on BMI (kg/m2): normal-weight BMI = 18.5–24.9, overweight BMI = 25.0–29.9, obese BMI = ≥30.0 (25).
Results for 100% OJ group: ++, significant increase (P ≤ 0.05); +, marginally significant increase (0.05 < P < 0.10); 0, no effect; -, marginally significant decrease (0.05 < P < 0.10); - -, significant decrease (P ≤ 0.05). Methods or assays used for measuring antioxidant capacity and lipid peroxidation are included in brackets (e.g., [FRAP assay], [ORAC assay], [TAS assay]).
Key findings exclude markers showing no difference between intervention groups.
Results from statistical tests of treatment arm comparisons with 100% OJ were not reported, so the table presents results of effects as described in each article's text.
Results from 2-factor repeated-measures ANOVA where separate treatment effects were not reported. Significance indicates time effects (i.e., change in the marker from baseline) after both meals irrespective of the treatments given with breakfast.
Within-group differences not reported. Overlap in reported mean ± SD values for before and after measures suggests no statistically significant changes in within-group hs-CRP for either blood or blond 100% OJ treatments.
Blood measures were taken before (t0′) and 30 min (t30′) and 24 h after (t24hr) participants underwent a single bout of exhaustive exercise. In results for 100% OJ, we report comparisons of baseline and post–juice supplementation at each time point (e.g., t30′ baseline compared with t30′ after supplementation).
Statistical significance for metabolites related to oxidative stress and inflammation was reported as calculated q-values (false discovery rates accounting for multiple comparisons and estimating reliability of results). For key findings, q ≤ 0.1 was considered statistically significant.
All markers of inflammation and oxidative stress reported by 22 included articles[1]
| Marker type | Articles, % | Specific markers |
|
|---|---|---|---|
| Antioxidants | 41 | Antioxidant capacity | 7 |
| GSH | 2 | ||
| GSSG | 2 | ||
| Cytokine suppressors (mRNA and/or protein expression) | 9 | SOCS-1 | 1 |
| SOCS-3 | 2 | ||
| SOCS-7 | 1 | ||
| Cytokines[ | 32 | IFN-γ* | 1 |
| IL-1β*[ | 2 | ||
| IL-4** | 2 | ||
| IL-6*[ | 5 | ||
| IL-10*** | 2 | ||
| IL-12* | 1 | ||
| TNF-α*[ | 5 | ||
| DNA damage | 18 | 8-OHdG | 2 |
| % DNA in tail | 1 | ||
| DNA strand breaks | 1 | ||
| Hemolysis rate | 1 | ||
| Micronuclei rate | 1 | ||
| Endotoxins | 9 | LPS | 2 |
| Enzymes | 9 | MMP-9 | 1 |
| MPO | 1 | ||
| NADPH oxidase subunit p47phox protein | 1 | ||
| p38 MAP kinase | 1 | ||
| p38, phosphorylated | 1 | ||
| Glycoproteins | 9 | E-selectin | 1 |
| LBP | 1 | ||
| Hormones | 5 | Leptin | 1 |
| Leukocytes | 5 | WBC | 1 |
| Lipid peroxidation | 36 | 8- | 1 |
| 8- | 1 | ||
| MDA | 6 | ||
| LPOs | 2 | ||
| Lipoproteins, pathological | 14 | OxLDL | 3 |
| Metabolites | 5 | 11-Dehydro-TXB2 | 1 |
| 9,10-DiHOME | 1 | ||
| 12,13-DiHOME | 1 | ||
| 9-HODE | 1 | ||
| 13-HODE | 1 | ||
| 5-HETE | 1 | ||
| 12-HETE | 1 | ||
| Other proteins | 50 | CRP | 2 |
| hs-CRP | 7 | ||
| NF-κB | 1 | ||
| Proteomes in PBMCs | 1 | ||
| VCAM-1 | 1 | ||
| Oxypurines | 5 | Hypoxanthine | 1 |
| Xanthine | 1 | ||
| Protein oxidation | 5 | Plasma protein carbonyl groups | 1 |
| Reactive oxygen species | 5 | ROS-PMN | 1 |
| ROS-MNC | 1 | ||
| Toll-like receptor (mRNA and/or protein expression) | 9 | TLR2 | 2 |
| TLR4 | 2 |
Two articles covering 1 study reported different outcomes. CRP, C-reactive protein; Dehydro-TXB2, Dehydrothromboxane B2; hs-CRP, high-sensitivity C-reactive protein; DiHOME, dihydroxyoctadecanoic acid; GSH, reduced glutathione; GSSG, oxidized glutathione; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; iso-, isoprostane; LBP, lipopolysaccharide-binding protein; LPO, lipid peroxidation; MAP, mitogen activated protein; MDA, malondialdehyde (a secondary lipid peroxidation marker); MMP, matrix metallopeptidase; MNC, mononuclear cell; MPO, myeloperoxidase; OxLDL, oxidized LDL; PBMC, peripheral blood mononuclear cell; PGF, prostaglandin F; PMN, polymorphonuclear cell; ROS, reactive oxygen species; SOCS, suppresser of cytokine signaling; TLR, Toll-like receptor; VCAM, vascular endothelial adhesion molecule; WBC, white blood cell; 8-OHdG, 8-hydroxy-2′-deoxyguanosine.
Cytokines: *proinflammatory, **adaptive immunity, ***anti-inflammatory.
Measured by 1 study as mRNA or protein expression of the marker in mononuclear cells (40).
FIGURE 2Random-effects model meta-analysis of crossover and parallel trials measuring hs-CRP in participants given 100% OJ and non-100% OJ interventions. 1Nonrandomized study; box sizes represent study weight. hs-CRP, high-sensitivity C-reactive protein; OJ, orange juice; ROB, risk of bias.
FIGURE 3Random-effects model meta-analysis of crossover trials measuring IL-6 in participants given 100% OJ and non-100% OJ interventions with subgroup analysis by study duration (acute or chronic). Box sizes represent study weight. OJ, orange juice; ROB, risk of bias.
FIGURE 4Random-effects model meta-analysis of crossover and parallel trials measuring MDA in participants given 100% OJ and non-100% OJ interventions. 1Different effect measures for parallel (net change) and crossover (net difference) trials. 2Nonrandomized study; Box sizes represent study weight. MDA, malondialdehyde; OJ, orange juice; ROB, risk of bias.